In2Clinical: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
In2Clinical
Largest movements
- Cash -€10,183
down €10,183 (-35.7%), from €28,488 to €18,304
mainly Net result for the year (-€5,472) and Tax, wage and social debts (-€4,370)
- Receivables within one year -€4,015
down €4,015 (-89.5%), from €4,484 to €469
of which Trade receivables: -€4,244
- Reserves -€5,472
down €5,472 (-32.6%), from €16,803 to €11,331
- Tax, wage and social debts -€4,370
down €4,370 (-77.5%), from €5,641 to €1,271
- Other debts -€3,332
no longer reported in 2025 (was €3,332)
- Trade debts -€929
down €929 (-84.5%), from €1,100 to €171
- Gross operating margin -€11,049
down €11,049, from €5,759 to -€5,291
- Taxes -€1,271
no longer reported in 2025 (was €1,271)
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €32,971 | €18,773 | -€14,198 | -43.1% |
| Current assets | 29/58 | €32,971 | €18,773 | -€14,198 | -43.1% |
| Amounts receivable within one year | 40/41 | €4,484 | €469 | -€4,015 | -89.5% |
| Trade receivables | 40 | €4,244 | - | -€4,244 | |
| Other amounts receivable | 41 | €240 | €469 | +€229 | +95.6% |
| Cash at bank and in hand | 54/58 | €28,488 | €18,304 | -€10,183 | -35.7% |
| Total equity and liabilities | 10/49 | €32,971 | €18,773 | -€14,198 | -43.1% |
| Equity | 10/15 | €22,803 | €17,331 | -€5,472 | -24.0% |
| Contributions | 10/11 | €6,000 | €6,000 | = | 0.0% |
| Reserves | 13 | €16,803 | €11,331 | -€5,472 | -32.6% |
| Distributable reserves | 133 | €16,803 | €11,331 | -€5,472 | -32.6% |
| Amounts payable | 17/49 | €10,168 | €1,442 | -€8,726 | -85.8% |
| Amounts payable within one year | 42/48 | €10,073 | €1,442 | -€8,631 | -85.7% |
| Trade debts | 44 | €1,100 | €171 | -€929 | -84.5% |
| Suppliers | 440/4 | €1,100 | €171 | -€929 | -84.5% |
| Taxes, remuneration and social security | 45 | €5,641 | €1,271 | -€4,370 | -77.5% |
| Taxes | 450/3 | €5,641 | €1,271 | -€4,370 | -77.5% |
| Other amounts payable | 47/48 | €3,332 | - | -€3,332 | |
| Accrued charges and deferred income | 492/3 | €95 | - | -€95 | |
| Gross operating margin | 9900 | €5,759 | -€5,291 | -€11,049 | |
| Operating profit (loss) | 9901 | €5,759 | -€5,291 | -€11,049 | |
| Financial charges | 65/66B | €155 | €181 | +€26 | +16.7% |
| Recurring financial charges | 65 | €155 | €181 | +€26 | +16.7% |
| Profit (loss) for the period before taxes | 9903 | €5,604 | -€5,472 | -€11,075 | |
| Income taxes | 67/77 | €1,271 | - | -€1,271 | |
| Profit (loss) for the period | 9904 | €4,332 | -€5,472 | -€9,804 | |
| Profit (loss) for the period to be appropriated | 9905 | €4,332 | -€5,472 | -€9,804 |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 26 October 2026 via checked.be.